Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.

Autor: Gharbharan A; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Jordans CCE; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., GeurtsvanKessel C; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., den Hollander JG; Maasstad Hospital, Rotterdam, The Netherlands., Karim F; Groene Hart Hospital, Gouda, The Netherlands., Mollema FPN; Haaglanden Medical Center, The Hague, The Netherlands., Stalenhoef-Schukken JE; OLVG Hospital, Amsterdam, The Netherlands., Dofferhoff A; Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Ludwig I; Bernhoven Hospital, Uden, The Netherlands., Koster A; Viecuri Medical Center, Venlo, The Netherlands., Hassing RJ; Rijnstate Hospital, Arnhem, The Netherlands., Bos JC; Reinier de Graaf Gasthuis, Delft, The Netherlands., van Pottelberge GR; ZorgSaam Hospital, Terneuzen, The Netherlands., Vlasveld IN; Martini Hospital, Groningen, The Netherlands., Ammerlaan HSM; Catharina Hospital, Eindhoven, The Netherlands., van Leeuwen-Segarceanu EM; Sint Antonius Hospital, Nieuwegein, The Netherlands., Miedema J; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., van der Eerden M; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Schrama TJ; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Papageorgiou G; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Te Boekhorst P; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Swaneveld FH; Unit of Transfusion Medicine, Sanquin Blood Supply, Amsterdam, The Netherlands., Mueller YM; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Schreurs MWJ; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., van Kampen JJA; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Rockx B; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Okba NMA; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Katsikis PD; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Koopmans MPG; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Haagmans BL; Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Rokx C; Erasmus MC, University Medical Center, Rotterdam, The Netherlands. c.rokx@erasmusmc.nl., Rijnders BJA; Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2021 May 27; Vol. 12 (1), pp. 3189. Date of Electronic Publication: 2021 May 27.
DOI: 10.1038/s41467-021-23469-2
Abstrakt: In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS-CoV-2 antibodies, no overall clinical benefit was observed. Using a comprehensive translational approach, we unravel the virological and immunological responses following treatment to disentangle which COVID-19 patients may benefit and should be the focus of future studies. Convalescent plasma is safe, does not improve survival, has no effect on the disease course, nor does plasma enhance viral clearance in the respiratory tract, influence SARS-CoV-2 antibody development or serum proinflammatory cytokines levels. Here, we show that the vast majority of patients already had potent neutralizing SARS-CoV-2 antibodies at hospital admission and with comparable titers to carefully selected plasma donors. This resulted in the decision to terminate the trial prematurely. Treatment with convalescent plasma should be studied early in the disease course or at least preceding autologous humoral response development.
Databáze: MEDLINE
Externí odkaz: